Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/1265
Full metadata record
DC FieldValueLanguage
dc.contributor.authorREG NO:BN0119004-
dc.date.accessioned2023-01-17T07:27:25Z-
dc.date.available2023-01-17T07:27:25Z-
dc.date.issued2022-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/1265-
dc.description.abstractBackground and objectives: Bladder cancer ranks 10th among the most frequently diagnosed cancers and are more common among men while prostate cancer ranks 2nd among the most frequently diagnosed cancer in men worldwide. Sometimes on routine hematoxylin and eosin (H&E) stain, it becomes difficult to differentiate between urothelial and prostate adenocarcinomas as they have similar morphological features in advanced stages. They also differ in their treatment modalities, staging and prognosis. The purpose of this study is to evaluate the role of GATA3 expression in differentiating urothelial carcinomas from adenocarcinomas of prostate and to correlate GATA3 positivity score with clinicopathological parameters.en_US
dc.language.isoen_USen_US
dc.publisherKLE Academy of Higher Education and Research, Belagavien_US
dc.subjectGATA3 marker, immunohistochemistry, urothelial carcinomas, prostate adenocarcinomas.en_US
dc.titleEvaluation of role of gata3 expression in Differentiating urothelial carcinomas from Adenocarcinomas of prostateen_US
dc.typeDissertationsen_US
Appears in Collections:Pathology

Files in This Item:
File Description SizeFormat 
RegNoBN0119004.pdf9.19 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.